Rexahn Pharma (RNN) Posts Narrower than Expected Q3 Loss of 1c/Share
Tweet
Share
E-mailGet Alerts RNN Hot Sheet
Join SI Premium – FREE
Rexahn Pharma (AMEX: RNN) reported Q3 EPS of ($0.01), $0.01 better than the analyst estimate of ($0.02).
The company ended the quarter with about $35.59 million in cash.
September 30, 2014 | December 31, 2013 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 14,971,660 | $ | 18,688,031 | ||||
Marketable securities (note 3) | 20,613,885 | 100,000 | ||||||
For earnings history and earnings-related data on Rexahn Pharma (RNN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Earnings, Momentum MoversRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
